New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market
The addressable patient population in the US could increase by 4.5 million if new trial is successful.
You may also be interested in...
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
John Thero insists company is focused on approval and launch, as interest in European rights grow.